Back to Search
MARK MOASSER, M.D.
M.D.
Medical Oncology Physician
NPI: 1417911751IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
A85674(CA)
Education
TUFTS UNIVERSITY SCHOOL OF MEDICINE
Class of 1988
Research & Publications (20)
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.
PMID 17471238·Oncogene·2007
6-review
Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy.
PMID 17968965·J Magn Reson Imaging·2007
7-preclinical
Targeting the function of the HER2 oncogene in human cancer therapeutics.
PMID 17486079·Oncogene·2007
6-review
The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer.
PMID 12088116·Breast Cancer Res Treat·2002
8-other
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
PMID 11585753·Cancer Res·2001
8-other
Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers.
PMID 19318475·Clin Cancer Res·2009
8-other
MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model.
PMID 19388114·J Magn Reson Imaging·2009
7-preclinical
The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation.
PMID 19349359·Am J Pathol·2009
8-other
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer.
PMID 19047117·Clin Cancer Res·2008
3-trial
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.
PMID 18498248·Biochem J·2008
8-other
Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired.
PMID 18410794·Semin Oncol·2008
6-review
The epidermal growth factor receptor family: biology driving targeted therapeutics.
PMID 18259690·Cell Mol Life Sci·2008
6-review
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
PMID 17952589·Breast Cancer Res Treat·2008
2-rct
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
PMID 17206155·Nature·2007
8-other
The HER family and cancer: emerging molecular mechanisms and therapeutic targets.
PMID 17981505·Trends Mol Med·2007
6-review
Targeting HER proteins in cancer therapy and the role of the non-target HER3.
PMID 17667926·Br J Cancer·2007
6-review
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy.
PMID 16866685·J Am Geriatr Soc·2006
8-other
Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study.
PMID 16776787·J Am Geriatr Soc·2006
4-observational
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective.
PMID 16541322·Breast Cancer Res Treat·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1600 DIVISADERO ST
SAN FRANCISCO, CA 94115 - Phone
- (415) 353-7070
Quick Facts
- NPI
- 1417911751
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 38
- Publications
- 20
Are you this provider?
Claim Your Profile